Literature DB >> 23735833

Pharmacokinetics and pharmacodynamics of orally administered clonidine: a model-based approach.

R H Klein1, R Alvarez-Jimenez, R N Sukhai, W Oostdijk, B Bakker, H M Reeser, B E P B Ballieux, P Hu, E S Klaassen, J Freijer, J Burggraaf, A F Cohen, J M Wit.   

Abstract

BACKGROUND/AIMS: The oral clonidine test is a diagnostic procedure performed in children with suspected growth hormone (GH) deficiency. It is associated with untoward effects, including bradycardia, hypotension and sedation. Serum clonidine levels have not previously been assessed during this test.
METHODS: In 40 children referred for an oral clonidine test, blood samples were drawn for clonidine and GH. Vital statistics and sedation scores were recorded until 210 min post-dose. We explored the relationship between clonidine concentrations and effects such as GH peak and blood pressure.
RESULTS: Of 40 participants, 5 children were GH deficient. Peak clonidine concentrations of 0.846 ± 0.288 ng/ml were reached after 1 h. Serum levels declined slowly, with concentrations of 0.701 ± 0.189 ng/ml 210 min post-dose. A large interindividual variation of serum levels was observed. During the procedure, systolic blood pressure dropped by 12.8%, diastolic blood pressure by 19.7% and heart rate by 8.4%. Moderate sedation levels were observed. Concentration-effect modeling showed that the amount of GH available for secretion as determined by previous bursts was an important factor influencing GH response.
CONCLUSION: Clonidine concentrations during the test were higher than necessary according to model-based predictions. A lower clonidine dose may be sufficient and may produce fewer side effects.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23735833     DOI: 10.1159/000350819

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  3 in total

1.  Clonidine-stimulated growth hormone concentrations (cut-off values) measured by immunochemiluminescent assay (ICMA) in children and adolescents with short stature.

Authors:  Maria de Fátima Borges; Flávia Carolina Cândida Teixeira; Aline Karin Feltrin; Karina Alvarenga Ribeiro; Gabriel Antonio Nogueira Nascentes; Elisabete Aparecida Mantovani Rodrigues Resende; Beatriz Pires Ferreira; Adriana Paula Silva; Heloísa Marcelina Cunha Palhares
Journal:  Clinics (Sao Paulo)       Date:  2016-04       Impact factor: 2.365

2.  Does dexmedetomidine combined with levobupivacaine in inferior alveolar nerve blocks among patients undergoing impacted third molar surgery control postoperative morbidity?

Authors:  Shweta Murlidhar Patil; Anendd Jadhav; Nitin Bhola; Pawan Hingnikar; Krutarth Kshirsagar; Dipali Patil
Journal:  J Dent Anesth Pain Med       Date:  2022-03-25

3.  Evaluating the transition from dexmedetomidine to clonidine for agitation management in the intensive care unit.

Authors:  Kimberly Terry; Rachel Blum; Paul Szumita
Journal:  SAGE Open Med       Date:  2015-12-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.